News
Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...
The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...
1don MSN
RFK Jr.’s Vaccine Court Spin
Health and Human Services Secretary Robert F. Kennedy Jr. misrepresented the country’s compensation program for those who are ...
1don MSN
Medicine bottles, capsules, razors, and combs come together to honor Philly’s pharmaceutical history
The Philadelphia College of Pharmacy was the first pharmacy college in North America. And for 30 years, the historic ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Merck trades at a low P/E with strong financials, Keytruda growth, and a solid 3.9% yield, while its pipeline offsets future risks. Read why MRK stock is a buy.
The recent portfolio rebalance increased FDL's risk and volatility, with 55% concentration in its top 10 holdings. Read why I ...
We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Merck & Co., Inc. (NYSE:MRK) is one of ...
Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...
Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...
Opinion
2dOpinion
Zacks Investment Research on MSNTop Analyst Reports for Merck, Palo Alto & Freeport
Thursday, August 14, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Merck & Co.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results